LDL cholesterol and atherosclerosis: The evidence

The lipid theory of atherosclerosis dates back more than a century. Despite this, some authors have questioned the relevance of hypercholesterolaemia in its development. Multiple experimental, epidemiological, and clinical evidence underpins this association. Atherosclerotic cardiovascular disease r...

Descripción completa

Detalles Bibliográficos
Autores: Guijarro, C, Cosin-Sales, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p10852
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/10852
Access Level:acceso abierto
Palabra clave:LDL cholesterol
Atherosclerosis
Lipid theory
Mendelian randomization
Clinical trials
id ES_2e51c1c36672bb68db5ea8bbd1d71ed4
oai_identifier_str oai:fisabio.fundanetsuite.com:p10852
network_acronym_str ES
network_name_str España
repository_id_str
spelling LDL cholesterol and atherosclerosis: The evidenceGuijarro, CCosin-Sales, JLDL cholesterolAtherosclerosisLipid theoryMendelian randomizationClinical trialsThe lipid theory of atherosclerosis dates back more than a century. Despite this, some authors have questioned the relevance of hypercholesterolaemia in its development. Multiple experimental, epidemiological, and clinical evidence underpins this association. Atherosclerotic cardiovascular disease remains as the major cause of mortality in the world. Recent genetic studies of Mendelian randomisation and randomised clinical trials aimed at LDL cholesterol reduction, are summarised in this article. They, unequivocally ratify the aetiological role of LDL cholesterol in the development of atherosclerosis. Thus, LDL cholesterol lowering is the cornerstone of lipid lowering therapy for the reduction of cardiovascular complications of atherosclerosis (c) 2021 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Arteriosclerosis.ELSEVIER2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/10852Clinica e Investigacion en ArteriosclerosisISSN: 02149168ISSNe: 15781879reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p108522026-06-11T12:45:17Z
dc.title.none.fl_str_mv LDL cholesterol and atherosclerosis: The evidence
title LDL cholesterol and atherosclerosis: The evidence
spellingShingle LDL cholesterol and atherosclerosis: The evidence
Guijarro, C
LDL cholesterol
Atherosclerosis
Lipid theory
Mendelian randomization
Clinical trials
title_short LDL cholesterol and atherosclerosis: The evidence
title_full LDL cholesterol and atherosclerosis: The evidence
title_fullStr LDL cholesterol and atherosclerosis: The evidence
title_full_unstemmed LDL cholesterol and atherosclerosis: The evidence
title_sort LDL cholesterol and atherosclerosis: The evidence
dc.creator.none.fl_str_mv Guijarro, C
Cosin-Sales, J
author Guijarro, C
author_facet Guijarro, C
Cosin-Sales, J
author_role author
author2 Cosin-Sales, J
author2_role author
dc.subject.none.fl_str_mv LDL cholesterol
Atherosclerosis
Lipid theory
Mendelian randomization
Clinical trials
topic LDL cholesterol
Atherosclerosis
Lipid theory
Mendelian randomization
Clinical trials
description The lipid theory of atherosclerosis dates back more than a century. Despite this, some authors have questioned the relevance of hypercholesterolaemia in its development. Multiple experimental, epidemiological, and clinical evidence underpins this association. Atherosclerotic cardiovascular disease remains as the major cause of mortality in the world. Recent genetic studies of Mendelian randomisation and randomised clinical trials aimed at LDL cholesterol reduction, are summarised in this article. They, unequivocally ratify the aetiological role of LDL cholesterol in the development of atherosclerosis. Thus, LDL cholesterol lowering is the cornerstone of lipid lowering therapy for the reduction of cardiovascular complications of atherosclerosis (c) 2021 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Arteriosclerosis.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/10852
url https://fisabio.portalinvestigacion.com/publicaciones/10852
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv Clinica e Investigacion en Arteriosclerosis
ISSN: 02149168
ISSNe: 15781879
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405396187217920
score 15,81155

Similares en LA Referencia